At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial
In Brief
A Phase 2 clinical trial evaluating Chloroquine Standard Dose (500mg/week), Chloroquine Low Dose (250mg/week), and 1 other intervention for Carcinoma, Intraductal, Noninfiltrating and 2 related conditions. Completed, enrolled 12 participants across 4 sites.
Detailed Summary
The purpose of this study is to test the hypothesis that chloroquine will reduce the ability of ductal carcinoma in situ (DCIS) to survive and spread. Participants will receive either chloroquine standard dose (500mg/week) or chloroquine low dose (250mg/week) for 1 month prior to surgical removal of the tumor.
Study Details
Timeline
Interventions
Patients will receive chloroquine (500 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
Patients will receive chloroquine (250 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
Patients diagnosed with DCIS will undergo a breast biopsy prior to the start of study treatment. This biopsy is entirely voluntary and is not required to remain in the study. The biopsy will allow researchers to study the tissue for biomarkers and to determine how the DCIS tissue changes during treatment. Additional samples of the DCIS tissue will be collected at the time of surgery.